1Marti MJ,Tolosa E,Campdelacreu J.Clinical overview of the synucleinopathies.Mov Disord,2003,18:S21-S27.
2Dev KK,Hofele K,Barbieri S,et al.Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.Neuropharmacology,2003,45:14-44.
3Clayton DF,George JM.Synucleins in synaptic plasticity and neurodegenerative disorders.J Neurosci Res,1999,58:120-129.
4Jenco JM,Rawlingson A,Daniels B,et al.Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins.Biochemistry,1998,37: 4901-4909.
5Ostrerova N,Petrucelli L,Farrer M,et al.alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.J Neurosci,1999,19: 5782-5791.
6Jellinger KA.Neuropathological spectrum of synucleinopathies.Mov Disord,2003,18:S2-S12.
7Iwai A.Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.Biochim Biophys Acta,2000,1502:95-109.
8Iseki E,Marui W,Kosaka K,et al.Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease.Neurosci Lett,1999,265: 9-12.
9Tu PH,Galvin JE,Baba M,et al.Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.Ann Neurol,1998,44: 415-422.
10Gosavi N,Lee HJ,Lee JS,et al.Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion.J Biol Chem,2002,277:48984-48992.
